BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

900 related articles for article (PubMed ID: 18455473)

  • 41. Epstein-Barr virus immune response in high-risk nasopharyngeal carcinoma families in Greenland.
    Friborg J; Jarrett RF; Liu MY; Falk KI; Koch A; Olsen OR; Duncan P; Wohlfarht J; Chen JY; Melbye M
    J Med Virol; 2007 Dec; 79(12):1877-81. PubMed ID: 17935169
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
    Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
    Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Significance of virus-specific antibodies to EBV-antigens in patients with nasopharyngeal carcinoma (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1979 Dec; 58(12):911-5. PubMed ID: 231716
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta/IgG, EBNA1/IgA, VCA/IgA and EA/IgA].
    Cai YL; Zheng YM; Cheng JR; Wang W; Zhang YN; Wang WH; Wu YS; Zhong WM; Li J; Mo YK
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Mar; 30(3):509-11. PubMed ID: 20335122
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EBV-specific humoral antibodies in nasopharyngeal carcinoma patients in Cuba.
    Ruiz R; Gurtsevich V; Le Riverend E
    Neoplasma; 1979; 26(2):125-31. PubMed ID: 224330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic value of measuring Epstein-Barr virus (EBV) DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin A (IgA) and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Fachiroh J; Paramita DK; Tan IB; Haryana SM; Middeldorp JM
    J Clin Microbiol; 2005 Jul; 43(7):3066-73. PubMed ID: 16002393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Purified hexameric Epstein-Barr virus-encoded BARF1 protein for measuring anti-BARF1 antibody responses in nasopharyngeal carcinoma patients.
    Hoebe EK; Hutajulu SH; van Beek J; Stevens SJ; Paramita DK; Greijer AE; Middeldorp JM
    Clin Vaccine Immunol; 2011 Feb; 18(2):298-304. PubMed ID: 21123521
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma.
    Tong JH; Tsang RK; Lo KW; Woo JK; Kwong J; Chan MW; Chang AR; van Hasselt CA; Huang DP; To KF
    Clin Cancer Res; 2002 Aug; 8(8):2612-9. PubMed ID: 12171892
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EBV specific antibody-based and DNA-based assays in serologic diagnosis of nasopharyngeal carcinoma.
    Chan KH; Gu YL; Ng F; Ng PS; Seto WH; Sham JS; Chua D; Wei W; Chen YL; Luk W; Zong YS; Ng MH
    Int J Cancer; 2003 Jul; 105(5):706-9. PubMed ID: 12740922
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States.
    O TM; Yu G; Hu K; Li JC
    Otolaryngol Head Neck Surg; 2007 Jun; 136(6):992-7. PubMed ID: 17547994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Significance of detection of serum sialic acid and Epstein-Barr virus VCA-IgA in diagnosis and monitoring radiotherapy effectiveness in nasopharyngeal carcinoma patients].
    Jiang LN; Dai LC; He JF; Chen YW; Ma ZH
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):30-2. PubMed ID: 16816858
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Detection of Epstein-Barr virus DNA in plasma/serum: a useful serological indicator for diagnosis of nasopharyngeal carcinoma.
    Mai S; Zong Y; Zhang M; Zhong B; Lin S
    Chin Med J (Engl); 2002 Dec; 115(12):1895-7. PubMed ID: 12622949
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of EBV antibody EA-IgA, Rta-IgG and VCA-IgA and SA in serum and the implication of combined assay in nasopharyngeal carcinoma diagnosis.
    Xia C; Zhu K; Zheng G
    Int J Clin Exp Pathol; 2015; 8(12):16104-10. PubMed ID: 26884888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
    Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
    Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Humoral immune response in Epstein-Barr virus infections. I. Elevated serum concentration of the IgG1 subclass in infectious mononucleosis and nasopharyngeal carcinoma.
    Kaschka WP; Hilgers R; Skvaril F
    Clin Exp Immunol; 1982 Jul; 49(1):149-56. PubMed ID: 6290114
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The significance of serum IgM IgA and IgG antibodies specific for Epstein-Barr virus as determined by immunoperoxidase assay in the rapid diagnosis of infectious mononucleosis.
    Hadar T; Margalith M; Sagiv E; Sarov B; Sarov I
    Isr J Med Sci; 1995 May; 31(5):280-3. PubMed ID: 7759222
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
    Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
    AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Study on the serological diagnosis of Epstein-Barr virus among patients with mononucleosis].
    Liu CY; Yan J; Liu YY; Xie ZD
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Sep; 28(9):898-900. PubMed ID: 18251276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.